Neuroimaging

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Retrieved on: 
onsdag, maj 8, 2024
Neurodegenerative disease, Neuroimaging, MSA, Safety, Pharmacokinetics, Food, ASX, Pathology, Disease, Data monitoring committee, Patient, DMC, Biomarker, Clinical trial, Therapy, ATH, Food and Drug Administration, SAN, Pharmaceutical industry

MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended the ATH434-201 Phase 2 study continue as planned. The ATH434-201 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare neurodegenerative disease with no approved treatments to slow or stop its progression.

Key Points: 
  • The DMC conducted its prespecified review of unblinded clinical data from study participants.
  • The plan for the DMC to review clinical data from the trial has been cleared with the U.S. Food and Drug Administration.
  • “We are pleased to report that the Data Monitoring Committee for our ATH434-201 Phase 2 clinical trial has again determined that there are no safety concerns and that the study can continue as planned,” said David Stamler, M.D., Chief Executive Officer of Alterity.
  • Additional information on the Phase 2 trial can be found by ClinicalTrials.gov Identifier: NCT05109091 .

UT Health San Antonio-led STRONG STAR Consortium secures $17 million in DOD research funding for brain injuries, PTSD and more

Retrieved on: 
tisdag, april 30, 2024
Neuroimaging, University, Psychiatry, Post-traumatic stress disorder, Tinnitus, DOD, Trauma, Risk, Veterans' affairs, PTSD, Sleep, CQD, University of Texas System, Doctor of Philosophy, Research, Suicidal ideation, Military personnel, Concussion, Headache, Veteran, Cognitive processing therapy, Patient, STRONG, Workforce, Brain, Traumatic brain injury, Clinical trial, Function (mathematics), Ketamine, Chronic pain, SAN, Defense, Nursing

SAN ANTONIO, April 29, 2024 /PRNewswire-PRWeb/ -- In a recent round of grant awards, the STRONG STAR Consortium based at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) was selected by the U.S. Department of Defense for a total of $17 million in funding to launch eight new research projects focused on traumatic brain injury and psychological health.

Key Points: 
  • "Another is tinnitus, which is a persistent ringing in the ears that can develop after a brain injury.
  • Tinnitus is also commonly comorbid with PTSD, and it both contributes to and is impacted by psychological distress."
  • Some of these projects will be led by UT Health San Antonio investigators and others by STRONG STAR collaborators at other institutions, with research participants from a variety of military and VA study sites.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver of San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of $413 million.

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Retrieved on: 
onsdag, april 17, 2024
Molecule, Neuroimaging, American Academy, Brain, Iron, Oxidative stress, MSA, AFL, Poster, Disease, Vanderbilt University, Substantia nigra, Plasma, ASX, Pathology, Neurofilament, Forecasting, Macaque, Nerve, Multiple system atrophy, Patient, Treatment, Observational study, AAN, CSF, Neuron, Biomarker, Annual general meeting, Vanderbilt University Medical Center, Therapy, Cerebrospinal fluid, Parkinsonism, ATH, Frasier, SAN, Medical imaging

MELBOURNE, Australia and SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters were presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA. Featured presentations described the Company’s work in Parkinson’s disease and Multiple System Atrophy (MSA), including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinical trial.

Key Points: 
  • Featured presentations described the Company’s work in Parkinson’s disease and Multiple System Atrophy (MSA), including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinical trial.
  • At AAN we reported the baseline characteristics from our ATH434-201 Phase 2 trial including fluid biomarkers and neuroimaging data.
  • The data showed increased iron in areas of pathology and elevated plasma Neurofilament Light Chain (NfL) levels at baseline that correlated significantly with disease severity.
  • Plasma NfL significantly increased over 12 months, and both plasma and CSF NfL were associated with disease progression in MSA.

NYU Langone Neurologists Present Latest Clinical Findings & Research at AAN 2024

Retrieved on: 
lördag, april 13, 2024
Neuroimaging, American Academy, Brain, MCI, Stroke, White matter, Risk, Professor, News, NYU Langone Health, Doctor of Philosophy, Research, Appreciation, NYU, Deficit spending, Patient, AAN, Neurosurgery, Headache, Prevalence, MRI, Job satisfaction, Faculty, DSM-IV codes, Philip, Traumatic brain injury, Migraine, Practice, Biomarker, Annual general meeting, Organization, Growth, Medical imaging

DENVER, April 13, 2024 /PRNewswire/ -- Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual Meeting, April 13 to 18, in Denver.

Key Points: 
  • DENVER, April 13, 2024 /PRNewswire/ -- Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual Meeting, April 13 to 18, in Denver.
  • U.S. News & World Report's "Best Hospitals" ranks NYU Langone the No.
  • Researchers at NYU Langone surveyed 90 clinicians, residents, and fellows to identify the best methods of showing neurologists that they are valued in order to improve their job satisfaction and reduce burnout.
  • Further research is warranted to validate these findings and their potential to enhance early detection and intervention strategies for Alzheimer's disease.

EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING

Retrieved on: 
fredag, april 12, 2024
Amyloid, Angioedema, Brain, Anticoagulant, Neuroimaging, Patient, Vascular malformation, Lecanemab, Siderosis, Dementia, Cell, Seizure, ARIA, Risk, Aspirin, Focal neurologic signs, Nausea, Cerebral edema, Dizziness, Paracetamol, Arthralgia, Cerebral amyloid angiopathy, Effectiveness, Genetic testing, Intraparenchymal hemorrhage, Observation, Confusion, Alzheimer's disease, Intracerebral hemorrhage, Status epilepticus, Vomiting, Incidence, Aneurysm, Anaphylaxis, Headache, Hypersensitivity, Hypertension, MRI, Magnetic resonance imaging, Chills, Neuron, Bronchospasm, Fatal, Hypotension, Tissue plasminogen activator, Edema, Fever, Excipient, Pharmaceutical industry

Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

Key Points: 
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • There is no experience in patients who continued dosing through symptomatic ARIA-E or through asymptomatic, but radiographically severe, ARIA-E.
  • There is limited experience in patients who continued dosing through asymptomatic but radiographically mild to moderate ARIA-E.

TMS Health and Wellness Introduces Cutting-Edge Brain Scanning For Enhanced TMS Therapy Effectiveness

Retrieved on: 
måndag, april 8, 2024
Depression, Mindfulness, Magnetic resonance, Medicine, Health, Neuroimaging, Patient, TMS, Anxiety, Addiction, Chronic pain, Functional, Concierge medicine, Meditation, Wellness, Transcranial magnetic stimulation, Homeopathy, Neurofeedback, Map, Medical imaging

COSTA MESA, Calif., April 8, 2024 /PRNewswire-PRWeb/ -- In a significant advancement for treating anxiety, depression, and other mental health conditions, TMS Health and Wellness proudly announces the integration of comprehensive brain scanning technology into its Transcranial Magnetic Stimulation (TMS) Therapy protocols. This pioneering approach, leveraging Full Brain Scans and Functional MRI (fMRI) is set to revolutionize treatment customization, potentially elevating TMS Therapy's effectiveness to an unprecedented 90%.

Key Points: 
  • This pioneering approach, leveraging Full Brain Scans and Functional MRI (fMRI) is set to revolutionize treatment customization, potentially elevating TMS Therapy's effectiveness to an unprecedented 90%.
  • By utilizing detailed brain imaging to map and understand each patient's unique neural patterns, TMS Health and Wellness can customize the application of TMS Therapy with greater precision than ever before.
  • The clinic's expanded services now include:
    With the introduction of brain scanning technology, TMS Health and Wellness reinforces its dedication to pioneering in the mental health space and its mission of treating the "whole person."
  • TMS Therapy enhanced with Full Brain Scans and Functional MRI is available now.

Manifest Technologies Emerges From Stealth With Strategic Investors and Prepares for Next Development Stage of AI-Powered Precision Neuroscience

Retrieved on: 
torsdag, mars 28, 2024
Neurology, Biotechnology, Pharmaceutical, Managed Care, Health, Artificial Intelligence, Health Technology, Technology, Entrepreneurship, Psychiatry, Yale University, Associate, Partnership, Myenteric plexus, Patient, CNS, Neuroimaging, Research, DSM-IV codes, Dartmouth College, AI, Psychology, Yale School of Medicine, NIH, Johnson & Johnson, Drug development, CMO, Map

Today, over one billion people on the planet suffer from some form of a brain disorder, with an estimated economic burden of as much as $8.5 trillion per year.

Key Points: 
  • Today, over one billion people on the planet suffer from some form of a brain disorder, with an estimated economic burden of as much as $8.5 trillion per year.
  • There is an urgent unmet need for more rapid and precise development of treatments that are ultimately delivered to the right person at the right time.
  • Recent acquisitions in the neuroscience space highlight the need for tools that can optimize clinical trials and drive more efficient drug development based on precise neural targets.
  • Manifest is actively working with Johnson & Johnson to deploy its solutions across several programs.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
onsdag, mars 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
onsdag, mars 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Matter Neuroscience Secures $26M in Funding to Cure Unhappiness

Retrieved on: 
tisdag, februari 27, 2024
Neuroimaging, DEPT, Happiness, Diagnosis, Anxiety, Mental health, Interventional radiology, Emotion, Research, Biomedical engineering, Professor, Collaborative Fund, Capitalism, Polaris Partners, Capital, Imaging, Neurology, Risk, Trial of the century, Health, Human Brain Project, Medical imaging, Brain mapping, ARCH, Bayer, Bouchon, Maastricht University, Biological engineering, Psychiatry, Science, Magnetic resonance, ARCH Venture Partners, Good Worldwide, Addiction, Brain, Depression

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- Matter Neuroscience, the company working to unlock a deeper understanding of happiness and well-being by providing people with personalized insights into their brain chemistry emerges from stealth mode today. Matter announced it has received $26 million in funding, initial funding seeded by Polaris Partners and a more recent round co-led by ARCH Venture Partners, Polaris Partners, and Exor Ventures, and joined by Collaborative Fund and others. With this backing, Matter will bolster its efforts to pioneer solutions that address the unhappiness epidemic by transforming our understanding and management of mental well-being.

Key Points: 
  • With this backing, Matter will bolster its efforts to pioneer solutions that address the unhappiness epidemic by transforming our understanding and management of mental well-being.
  • Together with its collaboration partners, Matter Neuroscience will initiate three more clinical studies in 2024.
  • Matter also offers users access to educational materials and a lecture series on the neuroscience of happiness.
  • Matter Neuroscience was co-founded in 2019 with Ben Goldhirsh of GOOD Worldwide and the Goldhirsh Foundation, and Chris Shiflett of Faculty and Brooklyn Beta.